FSTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FSTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-11), F-star Therapeutics's share price is $7.12. F-star Therapeutics's Tangible Book per Share of Sep. 2022 for the quarter that ended in Sep. 2022 was $1.21. Hence, F-star Therapeutics's Price to Tangible Book Ratio of today is 5.88.
The historical rank and industry rank for F-star Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 3 years, F-star Therapeutics's highest Price to Tangible Book Ratio was 140.65. The lowest was 1.39. And the median was 3.06.
A closely related ratio is called PB Ratio. As of today, F-star Therapeutics's share price is $7.12. F-star Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2022 was $2.59. Hence, F-star Therapeutics's P/B Ratio of today is 2.75.
The historical data trend for F-star Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
F-star Therapeutics Annual Data | |||||||
Trend | Dec19 | Dec20 | Dec21 | ||||
Price-to-Tangible-Book | - | 9.89 | 1.66 |
F-star Therapeutics Quarterly Data | ||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 2.68 | 1.66 | 1.39 | 3.39 | 4.23 |
For the Biotechnology subindustry, F-star Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where F-star Therapeutics's Price-to-Tangible-Book falls into.
F-star Therapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2022 ) |
= | 7.12 | / | 1.211 | |
= | 5.88 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of F-star Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Geoffrey Race | director | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Edward Jr Benz | director | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Darlene M Deptula-hicks | officer: See Remarks | C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062 |
Eliot Forster | director, officer: PRESIDENT AND CEO | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Nessan Bermingham | director | 890 WINTER STREET, WALTHAM MA 02451 |
Louis Kayitalire | officer: CHIEF MEDICAL OFFICER | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Neil Brewis | officer: CHIEF SCIENTIFIC OFFICER | C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT |
Pamela M. Klein | director | 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748 |
Krol Patrick Johan Hendrik | director | GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS |
Garrett Winslow | officer: General Counsel and Secretary | 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748 |
Lori Firmani | officer: VP of Finance and Treasurer | 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748 |
Scott Andrew Smith | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Timothy P Clackson | director | C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Christiana Bardon | director, 10 percent owner | 86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748 |
Mpm Oncology Impact Management Lp | 10 percent owner | 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116 |
From GuruFocus
By PRNewswire PRNewswire • 07-13-2022
By GuruFocusNews GuruFocusNews • 06-09-2022
By PRNewswire PRNewswire • 07-08-2022
By PurpleRose PurpleRose • 07-20-2022
By Business Wire Business Wire • 07-16-2022
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 07-04-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By PRNewswire PRNewswire • 06-27-2022
By Business Wire Business Wire • 07-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.